Admaius Capital Partners has acquired a minority stake in Triquera B.V., the majority shareholder of Minapharm Pharmaceuticals, to enhance the availability of advanced biologic treatments across Africa and the Middle East.

Target Company Overview

Triquera B.V. is the parent company of Minapharm Pharmaceuticals and Chemical Industries S.A.E., a prominent pharmaceutical firm based in Egypt and a leading biopharmaceutical company in Africa. With over 25 years of experience in cellular and bioprocess engineering, Minapharm offers a vast portfolio of more than 100 life-saving and life-enhancing products, which include small molecules and complex, genetically engineered proteins. The company not only develops an impressive immunotherapy pipeline but also collaborates closely with its wholly-owned Berlin-based subsidiary, ProBioGen AG, which specializes in providing innovative technologies for monoclonal antibodies, protein, viral, and cell therapies, establishing itself as the only gene-to-market biopharmaceutical company in the region.

Industry Overview in Egypt

The pharmaceutical industry in Egypt is undergoing a significant transformation, driven by increased investments and strategic partnerships aimed at enhancing research and manufacturing capabilities. With a growing population and rising healthcare needs, there is a pressing demand for advanced pharmaceutical solutions, particularly in the biotechnology sector. Egypt's strategic location enables it to serve as a hub for biotech advancements across the Middle East and Africa, with the government actively supporting initiatives that enhance the industry’s competitive edge on a global scale.

Recent market developments indicate a positive trajectory for the biotechnology industry, as both domestic and international investors recognize the potential for growth. The infusion of capital into local companies like Minapharm positions the